TXMD News and Press, TherapeuticsMD Inc. From 05/24/23

2023-05-24 13:33:04 ET In its preliminary annual 2023 Russell indexes reconstitution, a total of 164 companies will be added and 319 deleted from the Russell microcap index. Following notable healthcare companies will be added and deleted from Russell microcap index: Notable additio...

2023-05-23 09:00:35 ET Summary TXMD is a pharmaceutical company that experienced a tremendous transformation in the last year, fully transforming into a royalty-only company. The company sold all its assets and paid down all its debt and is now expecting 8% of royalties plus $30 m...

2023-05-15 16:54:32 ET Therapeutics MD press release ( NASDAQ: TXMD ): Q1 GAAP EPS of -$0.24 beats by $0.87 . License and service revenues from continuing operations, which are revenues related to license agreements, were $0.4 million for the quarter ended March 31, 20...

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Financial Results Net Loss fro...

2023-04-10 09:47:38 ET Therapeutics MD press release ( NASDAQ: TXMD ): FY GAAP EPS of -$0.12. As of December 31, 2022, the Company’s cash on hand totaled $38.1 million compared with $64.9 million as of December 31, 2021. For further details see: Therapeuti...

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2022. “As a result of the transaction with Mayne Pharma Gro...

An agreement between TherapeuticsMD ( NASDAQ: TXMD ) and its interim CFO Michael Donegan has been terminated. Donegan was also serving as chief accounting officer and VP, finance. He is also entitled to separation benefits, including his salary for a year and COBRA benefits for tw...

- Mayne Pharma gains exclusive U.S. commercialization rights for TXMD’s products and acquires certain assets - - TXMD received approximately $153.1 million at closing; portion of proceeds used to repay all outstanding indebtedness under Sixth Street facility and redeem all outstand...

- TXMD to receive approximately $153.1 million in consideration at closing (including approximately $13.1 million for acquired net working capital), up to approximately $42.6 million in minimum royalty payments, and up to $30.0 million in additional milestone payments - - Mayne Pharma gai...

Therapeutics MD press release ( NASDAQ: TXMD ): Q3 GAAP EPS of -$3.13 misses by $1.09 . Revenue of $20.92M (-17.7% Y/Y) misses by $9.28M . As of September 30, 2022, the Company’s cash on hand totaled $27.1 million, compared with $65.1 million as of Decem...